Philips has substantially resolved the Respironics CPAP recall litigation with a US class settlement, removing the major equity overhang. The Diagnosis & Treatment (Image Guided Therapy, Ultrasound) division remains the highest-quality earnings engine, and Personal Health is structurally improving. China stimulus on hospital equipment procurement provides cyclical recovery. Margin expansion targets remain credible but require sustained execution. Premium imaging share gains versus GE HealthCare and Siemens Healthineers are uneven.
Thesis reviewed May 29, 2026
Koninklijke Philips NV is headquartered in Netherlands, which is currently showing moderate signals.
🇳🇱Netherlands66NEUTRALView Netherlands risk detail →🏥Healthcare28NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| UNH | UnitedHealth Group Inc. | 32 | +16% | ↓3% | AVOID |
| CVS | CVS Health Corporation | 32 | +15% | ↓3% | AVOID |
| ELV | Elevance Health Inc. | 32 | +7% | ↓3% | NEUTRAL |
| SYK | Stryker Corporation | 32 | +15% | ↓3% | EARLY |
| TEVA | Teva Pharmaceutical Industries Ltd. | 32 | +9% | ↓3% | NEUTRAL |
| DHR | Danaher Corporation | 32 | +11% | ↓3% | EARLY |
| TMO | Thermo Fisher Scientific Inc. | 32 | +11% | ↓3% | EARLY |
Investors who hold PHG may also have indirect exposure through these country funds.
Philips finalizes USD1.1bn Respironics consumer class action settlement
China VBP medical equipment procurement resumes orders for imaging
Estimates · Yahoo Finance · Not audited figures